Clinical efficacy of intracavernous injection of platelet lysate for erectile dysfunction.
Erectile dysfunction
Intracavernous injection
Platelet lysate
Platelet-rich plasma
Journal
BMC urology
ISSN: 1471-2490
Titre abrégé: BMC Urol
Pays: England
ID NLM: 100968571
Informations de publication
Date de publication:
29 Oct 2024
29 Oct 2024
Historique:
received:
25
04
2024
accepted:
21
10
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
epublish
Résumé
Among the emerging treatments for erectile dysfunction (ED), platelet-rich plasma (PRP), known for its ability to enhance tissue repair and regeneration, stands out as a promising therapeutic approach. In this innovative study, we aimed to assess the efficacy of intracavernous injections of platelet lysate (PL), a derivative of PRP, in improving erectile function among ED patients. We enrolled twenty-six patients, aged between 35 and 70 years (mean age 51.6 ± 11.3 years), who had been experiencing ED for over six months and had an International Index of Erectile Function-5 (IIEF-5) score of 21 or less. Participants received autologous PL injections intracavernously every two weeks for a total of five administrations. We assessed Erection Hardness Score (EHS) and International Index of Erectile Function-5 (IIEF-5) bi-weekly for 16 weeks and conducted penile Doppler ultrasounds pre- and post-treatment to record peak systolic velocity (PSV) and resistance index (RI). Before treatment, the mean EHS was 2.15 ± 0.88 and IIEF-5 was 10.92 ± 5.28. Remarkable improvements were observed post-treatment, with the EHS significantly increasing to 3.15 ± 0.83 (p < 0.05) and IIEF-5 to 17.23 ± 5.26 (p < 0.05). Penile Doppler ultrasound exhibited an increase in both PSV and RI post-treatment, with the rise in RI being statistically significant. Our findings indicate that intracavernous injections of PL substantially enhance erectile function, as evidenced by improvements in EHS, IIEF-5, and the RI of penile Doppler ultrasound, without hemorrhagic events or other adverse reactions apart from temporary pain at the injection site during the 16-week follow-up period. These encouraging results suggest that PL injections are a safe and effective treatment modality for patients with moderate ED, potentially providing a less invasive and more physiologically friendly alternative to current ED management strategies. The study received approval from the Institutional Review Board of National Taiwan University Hospital (IRB Number 202008061RIPC, date of registration 08/28/2020).
Sections du résumé
BACKGROUND
BACKGROUND
Among the emerging treatments for erectile dysfunction (ED), platelet-rich plasma (PRP), known for its ability to enhance tissue repair and regeneration, stands out as a promising therapeutic approach. In this innovative study, we aimed to assess the efficacy of intracavernous injections of platelet lysate (PL), a derivative of PRP, in improving erectile function among ED patients.
METHODS
METHODS
We enrolled twenty-six patients, aged between 35 and 70 years (mean age 51.6 ± 11.3 years), who had been experiencing ED for over six months and had an International Index of Erectile Function-5 (IIEF-5) score of 21 or less. Participants received autologous PL injections intracavernously every two weeks for a total of five administrations. We assessed Erection Hardness Score (EHS) and International Index of Erectile Function-5 (IIEF-5) bi-weekly for 16 weeks and conducted penile Doppler ultrasounds pre- and post-treatment to record peak systolic velocity (PSV) and resistance index (RI).
RESULTS
RESULTS
Before treatment, the mean EHS was 2.15 ± 0.88 and IIEF-5 was 10.92 ± 5.28. Remarkable improvements were observed post-treatment, with the EHS significantly increasing to 3.15 ± 0.83 (p < 0.05) and IIEF-5 to 17.23 ± 5.26 (p < 0.05). Penile Doppler ultrasound exhibited an increase in both PSV and RI post-treatment, with the rise in RI being statistically significant.
CONCLUSIONS
CONCLUSIONS
Our findings indicate that intracavernous injections of PL substantially enhance erectile function, as evidenced by improvements in EHS, IIEF-5, and the RI of penile Doppler ultrasound, without hemorrhagic events or other adverse reactions apart from temporary pain at the injection site during the 16-week follow-up period. These encouraging results suggest that PL injections are a safe and effective treatment modality for patients with moderate ED, potentially providing a less invasive and more physiologically friendly alternative to current ED management strategies.
TRIAL REGISTRATION
BACKGROUND
The study received approval from the Institutional Review Board of National Taiwan University Hospital (IRB Number 202008061RIPC, date of registration 08/28/2020).
Identifiants
pubmed: 39472866
doi: 10.1186/s12894-024-01633-2
pii: 10.1186/s12894-024-01633-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
237Informations de copyright
© 2024. The Author(s).
Références
Dong L, Chang D, Zhang X, Li J, Yang F, Tan K, et al. Effect of low-intensity extracorporeal shock Wave on the treatment of Erectile Dysfunction: a systematic review and Meta-analysis. Am J Mens Health. 2019;13(2):1557988319846749.
doi: 10.1177/1557988319846749
pubmed: 31027441
pmcid: 6487775
Matz EL, Pearlman AM, Terlecki RP. Safety and feasibility of platelet rich fibrin matrix injections for treatment of common urologic conditions. Investig Clin Urol. 2018;59(1):61–5.
doi: 10.4111/icu.2018.59.1.61
pubmed: 29333517
Zamani M, Yaghoubi Y, Movassaghpour A, Shakouri K, Mehdizadeh A, Pishgahi A, et al. Novel therapeutic approaches in utilizing platelet lysate in regenerative medicine: are we ready for clinical use? J Cell Physiol. 2019;234(10):17172–86.
doi: 10.1002/jcp.28496
pubmed: 30912141
Alkandari MH, Touma N, Carrier S. Platelet-Rich plasma injections for Erectile Dysfunction and Peyronie’s Disease: a systematic review of evidence. Sex Med Rev. 2022;10(2):341–52.
doi: 10.1016/j.sxmr.2020.12.004
pubmed: 34219010
Anastasiadis E, Ahmed R, Khoja AK, Yap T. Erectile dysfunction: is platelet-rich plasma the new frontier for treatment in patients with erectile dysfunction? A review of the existing evidence. Front Reprod Health. 2022;4:944765.
doi: 10.3389/frph.2022.944765
pubmed: 36303622
pmcid: 9580815
Schirmann A, Boutin E, Faix A, Yiou R. Pilot study of intra-cavernous injections of platelet-rich plasma (P-shot
doi: 10.1016/j.purol.2022.05.002
pubmed: 35697553
Shaher H, Fathi A, Elbashir S, Abdelbaki SA, Soliman T. Is platelet Rich plasma safe and effective in treatment of Erectile Dysfunction? Randomized Controlled Study. Urology. 2023;175:114–9.
doi: 10.1016/j.urology.2023.01.028
pubmed: 36736914
Tai HC, Tsai WK, Chang ML, Praveen Rajneesh C, Tseng XW, Hsu WC, et al. Intracavernous injection of platelet-rich plasma reverses erectile dysfunction of chronic cavernous nerve degeneration through reduction of prostate hyperplasia evidence from an aging-induced erectile dysfunction rat model. Faseb j. 2023;37(4):e22826.
doi: 10.1096/fj.202201443R
pubmed: 36856608
Protogerou V, Beshari SE, Michalopoulos E, Mallis P, Chrysikos D, Samolis AA et al. The combined use of stem cells and platelet lysate plasma for the treatment of Erectile Dysfunction: a pilot Study-6 months results. Med (Basel). 2020;7(3).
Geyik S. Comparison of the efficacy of low-intensity shock wave therapy and its combination with platelet-rich plasma in patients with erectile dysfunction. Andrologia. 2021;53(10):e14197.
doi: 10.1111/and.14197
pubmed: 34350629
Raheem OA, Natale C, Dick B, Reddy AG, Yousif A, Khera M, et al. Novel treatments of Erectile Dysfunction: review of the current literature. Sex Med Rev. 2021;9(1):123–32.
doi: 10.1016/j.sxmr.2020.03.005
pubmed: 32631812
Yiou R, Hamidou L, Birebent B, Bitari D, Lecorvoisier P, Contremoulins I, et al. Safety of Intracavernous Bone Marrow-Mononuclear cells for Postradical Prostatectomy Erectile Dysfunction: an Open dose-escalation pilot study. Eur Urol. 2016;69(6):988–91.
doi: 10.1016/j.eururo.2015.09.026
pubmed: 26439886
Gupta S, Paliczak A, Delgado D. Evidence-based indications of platelet-rich plasma therapy. Expert Rev Hematol. 2021;14(1):97–108.
doi: 10.1080/17474086.2021.1860002
pubmed: 33275468
Hesseler MJ, Shyam N. Platelet-rich plasma and its utility in medical dermatology: a systematic review. J Am Acad Dermatol. 2019;81(3):834–46.
doi: 10.1016/j.jaad.2019.04.037
pubmed: 31009668
Liu MC, Chang ML, Wang YC, Chen WH, Wu CC, Yeh SD. Revisiting the regenerative therapeutic advances towards Erectile Dysfunction. Cells. 2020;9(5).
Krzastek SC, Bopp J, Smith RP, Kovac JR. Recent advances in the understanding and management of erectile dysfunction. F1000Res. 2019;8.
Tas T, Cakiroglu B, Arda E, Onuk O, Nuhoglu B. Early clinical results of the tolerability, Safety, and efficacy of autologous platelet-rich plasma administration in Erectile Dysfunction. Sex Med. 2021;9(2):100313.
doi: 10.1016/j.esxm.2020.100313
pubmed: 33529814
pmcid: 8072172
Jiang YH, Lee PJ, Kuo HC. Therapeutic efficacy of urethral sphincter injections of platelet-rich plasma for the treatment of stress urinary incontinence due to intrinsic Sphincter Deficiency: a proof-of-Concept Clinical Trial. Int Neurourol J. 2021;25(1):51–8.
doi: 10.5213/inj.2040272.136
pubmed: 33504126
pmcid: 8022168
Long CY, Lin KL, Shen CR, Ker CR, Liu YY, Loo ZX, et al. A pilot study: effectiveness of local injection of autologous platelet-rich plasma in treating women with stress urinary incontinence. Sci Rep. 2021;11(1):1584.
doi: 10.1038/s41598-020-80598-2
pubmed: 33452330
pmcid: 7810841
Masieri L, Sessa F, Mari A, Campi R, Cito G, Verrienti P, et al. Intravesical application of platelet-rich plasma in patients with persistent haemorrhagic cystitis after hematopoietic stem cell transplantation: a single-centre preliminary experience. Int Urol Nephrol. 2019;51(10):1715–20.
doi: 10.1007/s11255-019-02223-0
pubmed: 31321678
Eryilmaz R, Simsek M, Aslan R, Beger B, Ertas K, Taken K. The effect of plasma rich platelet graft on post-operative complications in mid-penile hypospadias. Andrologia. 2020;52(7):e13652.
doi: 10.1111/and.13652
pubmed: 32436309
Jiang YH, Jhang JF, Hsu YH, Ho HC, Lin TY, Birder LA, et al. Urothelial health after platelet-rich plasma injection in intractable recurrent urinary tract infection: improved cell proliferation, cytoskeleton, and barrier function protein expression. Low Urin Tract Symptoms. 2021;13(2):271–8.
doi: 10.1111/luts.12364
pubmed: 33197967
Jiang YH, Kuo YC, Jhang JF, Lee CL, Hsu YH, Ho HC, et al. Repeated intravesical injections of platelet-rich plasma improve symptoms and alter urinary functional proteins in patients with refractory interstitial cystitis. Sci Rep. 2020;10(1):15218.
doi: 10.1038/s41598-020-72292-0
pubmed: 32939046
pmcid: 7495440
Aydin A, Sonmez MG, Oltulu P, Kocabas R, Ozturk Sonmez L, Taskapu HH, et al. Is there a difference in Platelet-Rich plasma application method and frequency to protect against urethral stricture? Urol J. 2020;18(6):663–9.
pubmed: 33037605
Sekerci CA, Tanidir Y, Sener TE, Sener G, Cevik O, Yarat A, et al. Effects of platelet-rich plasma against experimental ischemia/reperfusion injury in rat testis. J Pediatr Urol. 2017;13(3):317. e1- e9.
doi: 10.1016/j.jpurol.2016.12.016
Ozsoy E, Kutluhan MA, Akyuz M, Tokuc E, Urkmez A, Gumrukcu G, et al. Renoprotective effect of platelet-rich plasma in obstructive uropathy. Int Urol Nephrol. 2021;53(6):1073–9.
doi: 10.1007/s11255-021-02782-1
pubmed: 33515156
Ding XG, Li SW, Zheng XM, Hu LQ, Hu WL, Luo Y. The effect of platelet-rich plasma on cavernous nerve regeneration in a rat model. Asian J Androl. 2009;11(2):215–21.
doi: 10.1038/aja.2008.37
pubmed: 19151738
pmcid: 3735030
Huang YC, Wu CT, Chen MF, Kuo YH, Li JM, Shi CS. Intracavernous injection of autologous platelet-rich plasma ameliorates Hyperlipidemia-Associated Erectile Dysfunction in a rat model. Sex Med. 2021;9(2):100317.
doi: 10.1016/j.esxm.2020.100317
pubmed: 33529811
pmcid: 8072173
Wu CC, Wu YN, Ho HO, Chen KC, Sheu MT, Chiang HS. The neuroprotective effect of platelet-rich plasma on erectile function in bilateral cavernous nerve injury rat model. J Sex Med. 2012;9(11):2838–48.
doi: 10.1111/j.1743-6109.2012.02881.x
pubmed: 22906160
Wu YN, Wu CC, Sheu MT, Chen KC, Ho HO, Chiang HS. Optimization of platelet-rich plasma and its effects on the recovery of erectile function after bilateral cavernous nerve injury in a rat model. J Tissue Eng Regen Med. 2016;10(10):E294–304.
doi: 10.1002/term.1806
pubmed: 23950105
Wu YN, Liao CH, Chen KC, Chiang HS. CXCL5 cytokine is a major factor in Platelet-Rich plasma’s preservation of erectile function in rats after bilateral cavernous nerve Injury. J Sex Med. 2021;18(4):698–710.
doi: 10.1016/j.jsxm.2020.12.016
pubmed: 33741291
Zaghloul AS, Mahmoud ElNashar AER, GamalEl Din SF, Zaki Said S, Saad HM, Refaat Eldebs H, et al. Smoking status and the baseline international index of erectile function score can predict satisfactory response to platelet-rich plasma in patients with erectile dysfunction: a prospective pilot study. Andrologia. 2021;53(9):e14162.
doi: 10.1111/and.14162
pubmed: 34196015
Poulios E, Mykoniatis I, Pyrgidis N, Zilotis F, Kapoteli P, Kotsiris D, et al. Platelet-Rich plasma (PRP) improves erectile function: a Double-Blind, randomized, placebo-controlled clinical trial. J Sex Med. 2021;18(5):926–35.
doi: 10.1016/j.jsxm.2021.03.008
pubmed: 33906807
Panunzio A, Labate C, Zacheo F, Orlando R, Rizzo FL, Porcaro AB et al. Platelet-rich plasma intracavernosal injections for the treatment of primary organic erectile dysfunction: a systematic review and meta-analysis of contemporary controlled studies. Int J Impot Res. 2023.
Towe M, Peta A, Saltzman RG, Balaji N, Chu K, Ramasamy R. The use of combination regenerative therapies for erectile dysfunction: rationale and current status. Int J Impot Res. 2022;34(8):735–8.
doi: 10.1038/s41443-021-00456-1
pubmed: 34253869
Fadadu PP, Mazzola AJ, Hunter CW, Davis TT. Review of concentration yields in commercially available platelet-rich plasma (PRP) systems: a call for PRP standardization. Reg Anesth Pain Med. 2019.
Britt D, Blankstein U, Lenardis M, Millman A, Grober E, Krakowsky Y. Availability of platelet-rich plasma for treatment of erectile dysfunction and associated costs and efficacy: a review of current publications and Canadian data. Can Urol Assoc J. 2021;15(6):202–6.
pubmed: 33212009